BridgeBio Pharma reportedly in talks for $1B preferred equity from KKR, Sixth Street
Source: SeekingAlpha
2026-07-01 00:19:46 ET
Read the full article on Seeking Alpha
For further details see:
BridgeBio Pharma reportedly in talks for $1B preferred equity from KKR, Sixth Street
BridgeBio Pharma Inc.
NASDAQ: BBIO
BBIO Trading
-0.41% G/L:
$81.26 Last:
950,448 Volume:
$81.93 Open:
BBIO Latest News
July 02, 2026 07:30:00 am
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
July 01, 2026 07:30:00 am
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
June 28, 2026 04:00:00 pm
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
June 22, 2026 12:57:19 pm
International Regulatory Momentum Becoming Key Modern Drug Development Driver
$13,905,867,946
157,635,809
2.34%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
